Evidence map›Paper›PMID 39229810›Full record

ArticleHealth expectations : an international journal of public participation in health care and health policy2024

Aripiprazole/Sertraline Combination: Clinical and Cost-Effectiveness in Comparison With Quetiapine for the Treatment of Bipolar Depression (ASCEnD Trial)-Protocol for a Nested Qualitative Study.

Isobel Hoppe, Stuart Watson, Caroline Kemp, Fiona Turnbull, Firoza Davies, John Gibson, Lumbini Azim, Lauren Wall, Niraj Ahuja, Sarah Al-Ashmori and 3 more

Abstract read
In one paragraph

Article in Health expectations : an international journal of public participation in health care and health policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Reducing the Delay in the Diagnosis of Bipolar Disorder: A Qualitative Study.Health expectations : an international journal of public participation in health care and health policy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Isobel HoppeSchool of Medicine, Keele University, Newcastle, UK.ORCID 0009-0001-2593-3937
Stuart WatsonTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0002-2558-3367
Caroline KempMcPin Foundation, London, UK.
Fiona TurnbullMcPin Foundation, London, UK.
Firoza DaviesMcPin Foundation, London, UK.
John GibsonMcPin Foundation, London, UK.ORCID 0000-0003-1731-4869
Lumbini AzimCumbria, Northumberland, Tyne and Wear NHS Trust, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0003-3094-5366
Lauren WallCumbria, Northumberland, Tyne and Wear NHS Trust, Newcastle University, Newcastle upon Tyne, UK.
Niraj AhujaRegional Affective Disorders Service, Cumbria, Northumberland, Tyne and Wear NHS Trust, Newcastle upon Tyne, UK.ORCID 0000-0002-4949-7893
Sarah Al-AshmoriClinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.ORCID 0009-0003-6044-4674
Sally KeysMcPin Foundation, London, UK.
Thomas KabirDepartment of Psychiatry, University of Oxford, Oxford, UK.ORCID 0000-0001-8908-0964
Carolyn A Chew-GrahamSchool of Medicine, Keele University, Newcastle, UK.ORCID 0000-0002-9722-9981

Funding

This ASCEnD trial is funded by the National Institute for Health and Care Research (NIHR) (Project Reference Number NIHR132773). CC-G is part-funded by WM ARC.
6 · The paper itself

Abstract

introductionBipolar disorder is a recurrent mental health disorder with a prevalence rate of 1.4%. On average, there can be a delay of 9.5 years from the initial presentation of symptoms to a confirmed diagnosis. Individuals living with bipolar disorder have a reduced life expectancy. There is limited evidence regarding the effectiveness of antidepressants in treating bipolar disorder. The ASCEnD clinical trial will test the clinical and cost-effectiveness of the aripiprazole/sertraline combination in comparison with quetiapine for the treatment of bipolar depression (individuals who suffer from depressive episodes in bipolar disorder) and will include a nested qualitative study.

methodsThe qualitative study will use semi-structured interviews to explore pilot trial participants' and clinicians' perspectives on recruitment procedures, the acceptability of the intervention, the management of bipolar disorder and attitudes to medication combinations.

conclusionFindings will inform recruitment strategies and optimise training for the participating sites in the ASCEnD full trial. They will also help to illuminate the lived experience of people with bipolar disorder and the clinicians who work with people with bipolar disorder. The discussion will explore perspectives on the delay in diagnosis, having a diagnosis, the impact of living with bipolar disorder and attitudes to treatment, including drug combinations. PATIENT OR PUBLIC CONTRIBUTION: A Lived Experience Advisory Panel (LEAP) has been convened with the support of the McPin Foundation, which will contribute to the ASCEnD trial and its nested qualitative study to provide input on the design and delivery of the trial and qualitative study, analysis of qualitative data and dissemination of findings.

Indexed as

Antipsychotic AgentsAripiprazoleBipolar DisorderCost-Benefit AnalysisQualitative ResearchQuetiapine FumarateAdultAntidepressive AgentsDrug Therapy, CombinationFemaleHumansInterviews as TopicMaleAntidepressive AgentsAntipsychotic AgentsAripiprazoleQuetiapine Fumaratebipolar depressionbipolar disorderclinical trialmental healthnested qualitative studypatient and public involvement

Identifiers

PMID39229810
PMCPMC11372465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.